UnknownNot Applicable

The American Society of Hematology (ASH) Research Registry: A Multicenter Research Registry of Patients With Hematologic Disease

United States20,000 participantsStarted 2018-05-10

Plain-language summary

This is a multicenter, retrospective and prospective, long-term registry of patients with benign or malignant hematologic diseases, whether or not these patients were or were not treated with disease-specific treatments. Information will be collected on patient demographics, disease characteristics, genomic and molecular data, laboratory data, pathology, radiographic reports, clinical status, quality of life, medications, and dosing information. Where appropriate, these data structures may be based on a combination of Fast Healthcare Interoperability Resources (FHIR) , Consolidated-Clinical Data Architecture (C-CDA) and/or client-speciﬁc structure deﬁnitions.

Who can participate

Age range1 Year – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients (\>18 years of age) must have diagnostically- or investigator-confirmed benign or malignant hematologic disease. * For prospective data collection efforts within the ASH Registry that require informed consent, children (\<18 years of age) with hematologic disease whose parent/legal guardian consents on their behalf may be included. Exclusion Criteria: * Adults that are unable to consent. * Prisoners

What they're measuring

Minimal Residual Disease

Timeframe: Up to 5 Years

Trial details

NCT IDNCT03535220

SponsorAmerican Society of Hematology

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-12-31

View on ClinicalTrials.gov More Benign and Malignant Hematologic Diseases trials